The need for quadrivalent vaccine against seasonal influenza
The need for quadrivalent vaccine against seasonal influenza
复制标题
DOI：
10.1016/j.vaccine.2010.08.028
复制
发表时间：
2010-09-07
期刊：
影响因子：
5.5
通讯作者：
Belshe, Robert B.
中科院分区：
文献类型：
--
作者：
Belshe, Robert B.
季节性流感流行给公共卫生造成了巨大负担，导致了严重的发病率和死亡率。人类流感可由A型和B型流感病毒引起，尽管A型流感是大多数季节性流感感染的原因，但B型流感疾病在儿童和年轻人中很常见，并且每2-4年引起一次季节性流行。在季节性流行期间传播的流感毒株可以是A型流感毒株A/H1N1和A/H3 N2、流感B谱系B/维多利亚和B/Yamagata的毒株、或这些的任何组合。流感感染的发病率和死亡率负担意味着世界各地的公共卫生机构建议接种疫苗，以尝试预防季节性流行病。世界卫生组织（WHO）和美国食品药品监督管理局（FDA）推荐三价季节性流感疫苗，该疫苗含有两种主要的A型流感毒株和一种B型流感毒株（由于其流行率较低但仍很重要）。在流感B谱系之间几乎没有交叉反应性保护：这意味着对流行病毒的良好保护依赖于正确预测任何季节流行的流感B谱系。这已被证明是依赖于机会，在美国，在2001年至2010年之间的10个季节中的5个季节，针对流行的B型流感病毒的三价疫苗几乎没有提供保护。因此，显然需要含有流感A/H1 N1、A/H3 N2和B/维多利亚和B/Yamagata谱系毒株的四价流感疫苗，以改善针对流感B病毒的保护并降低流感B感染的发病率。(c)2010爱思唯尔有限公司版权所有。
Seasonal influenza epidemics represent a substantial public health burden, causing significant morbidity and mortality. Influenza in humans can be caused by influenza type A and type B viruses, and although influenza A is responsible for the majority of seasonal influenza infections, influenza B disease is common in children and young adults, and causes seasonal epidemics every 2-4 years. Influenza strains circulating during a seasonal epidemic may be influenza type A strains A/H1N1 and A/H3N2, strains of influenza B lineages B/Victoria and B/Yamagata, or any combination of these. The morbidity and mortality burden of influenza infections means that public health agencies worldwide recommend vaccination to try and protect against seasonal epidemics. The World Health Organization (WHO) and, in the United States of America (USA), the Food and Drug Administration (FDA), recommend trivalent seasonal influenza vaccines containing the two main influenza type A strains and, due to its lesser but still important prevalence, one influenza type B strain. There is little or no cross-reactive protection between the influenza B lineages: this means that good protection against the circulating virus relies on correctly predicting the prevalent influenza B lineage in any season. This has proved to be reliant on chance, and little or no protection has been provided in the USA by the trivalent vaccines against the circulating influenza B virus in 5 of the 10 seasons between 2001 and 2010. There is, therefore, a clear need for a quadrivalent influenza vaccine, containing influenza A/H1N1, A/H3N2, and B/Victoria and B/Yamagata lineage strains, to improve protection against influenza B virus and reduce the morbidity of influenza B infection. (c) 2010 Elsevier Ltd. All rights reserved.